Marked variation in heritability estimates of left ventricular mass depending on modality of measurement by Nethononda RM et al.
1Scientific RepoRtS |         (2019) 9:13556  | https://doi.org/10.1038/s41598-019-49961-w
www.nature.com/scientificreports
Marked variation in heritability 
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Bongani M. Mayosi  7, Martin farrall  3,8 & Hugh Watkins3,8
Left ventricular (LV) hypertrophy is a strong risk factor for heart failure and cardiovascular death. ecG 
measures of LV mass are estimated as heritable in twin and family-based analyses and heritability 
estimates of LV mass measured by echocardiography are lower. We hypothesised that cMR-derived 
measurements, being more precise than echocardiographic measurements, would advance our 
understanding of heritable LV traits. We phenotyped 116 British families (427 individuals) by CMR and 
ecG, and undertook heritability analyses using variance-components (QtDt) and GWAS Snp-based 
(GctA-GReML) methods. ecG-based traits such as LV mass and Sokolow-Lyon duration showed 
substantial estimates of heritability (60%), whereas CMR-derived LV mass was only modestly heritable 
(20%). However, the ECG LV mass was positively correlated with the lateral diameter of the chest 
(rho = 0.67), and adjustment for this attenuated the heritability estimate (42%). Finally, CMR-derived 
right ventricular mass showed considerable heritability (44%). Heritability estimates of LV phenotypes 
show substantial variation depending on the modality of measurement, being greater when measured 
by ECG than CMR. This may reflect the differences between electrophysiological as opposed to 
anatomical hypertrophy. However, ECG LV hypertrophy traits are likely to be influenced by genetic 
association with anthropometric measures, inflating their overall measured heritability.
Left ventricular hypertrophy (LVH) and mass (LVM), whether measured with ECG or echocardiography, is a 
strong predictor of cardiovascular morbidity and mortality1. However, prognostic information provided by ECG 
is independent but complementary to that provided by echocardiography2. An explanation for this discrepancy 
may derive from the fact that the ECG LVM reflects electrical activities within myocardium, a property of the 
mass and electrophysiological state of cardiomyocytes, and electrical impedance between the heart and the skin; 
whereas echocardiographic LVM reflects a combination of myocardial and interstitial mass. We have previ-
ously collected ECG and echocardiographic data from a series of white British families ascertained through a 
hypertensive proband and found that ECG-derived mass was more heritable than Echo-derived LVM with the 
Sokolow-Lyon voltage index showing the highest heritability3. One possible explanation for this finding was that 
high variability of echocardiography in quantifying LVM and wall thickness could mask the heritability of these 
phenotypic traits compared to ECG-based measurements. Cardiac magnetic resonance (CMR) has been shown 
to be highly accurate and reproducible in quantification of left and right ventricular volumes, mass and ejection 
fraction4,5. These observations led to the hypothesis that more accurate quantification of LV phenotypes by CMR 
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could provide better assessment of LV heritability estimates compared to those obtained by echocardiography. 
Thus CMR might resolve heritable LVH traits potentially strongly linked to cardiovascular mortality and morbid-
ity that are optimally tractable to genetic analysis.
We therefore re-phenotyped the British family panel using CMR to measure left and right ventricular volumes 
and mass. We also conducted genome-wide genotyping enabling estimation of SNP-based heritability and con-
duct of a GWAS for LVM. These data allow a direct comparison of heritability estimates of ECG-derived indices 
of LVH with those obtained by CMR.
Results
population characteristics. Baseline characteristics of the study population are shown in Table 1. The 
mean age was 59.7 ± 13 years and 52.5% were females. In general the study population was overweight with a BMI 
of 28.1 ± 4.8. Office systolic and diastolic blood pressures (BP) were 140.5 ± 18.2 and 81.5 ± 10.3 mmHg, whereas 
the mean 24 h systolic and diastolic BP were 130.8 ± 13.3 and 77.3 ± 7.9 mmHg, respectively. Both these blood 
pressures were direct measured BP without adjustment. Based on the 2018 ESH/ESC guidelines on hypertension6 
both the office systolic blood pressure (SBP) and the 24-h ambulatory SBP were in the hypertension range.
Measures of left ventricular phenotypes. Table 2 lists descriptive statistics for the ECG measures of 
LVH and LVM. Twenty-two individuals could not be phenotyped due to bundle branch block (n = 12), atrial 
fibrillation (n = 5), or presence of permanent pacemaker (n = 5). Both the Sokolow-Lyon voltage (21.1 ± 6.5 mV 
in males; 19.0 ± 5.3 mV in females) and the Cornell voltage (12.9 ± 4.8 mV in males; 11.7 ± 4.8 mV in females) 
were below the respective cut-off values (Sokolow-Lyon of 35 mV for both genders; and Cornel voltage of 28 mV 
in males and 20 mV in Females) for the diagnosis of LVH7. The duration products of these indices were similarly 
below their respective LVH thresholds of 2840 mV.ms (Sokolow-Lyon duration) and 2440 mV.ms (Cornell dura-
tion). Finally, the calculated ECG LV masses [mean of 130.2 g (114.9 g –143.5 g)] were also in the normal range.
Table 3 lists descriptive statistics for CMR LV volumes and mass and derivative indices (by body surface 
area). Twenty-two subjects were excluded from this analysis due to claustrophobia (n = 8), presence of a pace-
maker (n = 5), obesity (n = 2), unwillingness to undergo examination (n = 5), aneurysm clips (n = 1), or back-
ache (n = 1). In general left and right ventricular volumes indices were in the same ranges as those previously 
reported8. Males had larger ventricular volumes than females. LVM indices were generally higher than those 
previously reported, in keeping with the ascertainment strategy for this cohort.
estimates of heritability. The numbers of families and individuals with phenotype data available for 
heritability analysis are shown in supplementary Table 1. Families with a solitary phenotyped member can 
contribute to the GCTA-GREML heritability estimates (h2IBS>0.05) if their genotype data indicate cryptic rela-
tionships, but not the QTDT variance-component estimates (h2QTDT), which rely on self-reported relationships 
and family structures. Table 4 and Supplementary Tables 3–6 show heritability estimates for ECG and CMR 
LV hypertrophy phenotypes after adjustment for significant (P-value < 0.01) sources of covariation. Consistent 
with previously published data from this cohort3, ECG Sokolow-Lyon voltage showed moderate heritability in 
both the variance-components (QTDT) and IBS threshold (GCTA-GREML) analyses (h2QTDT, 35 ± 9%; h2IBS>0.05, 
Age, yrs 59.7 ± 13
Females, n (%) 228 (52.5)
Weight (kg) 79.3 (68.7–89.2)
Height (m) 1.69 ± 0.09
BMI (m/kg2) 28.1 ± 4.8
BSA (m2) 1.53 ± 0.24
SBP (mmHg) 140.5 ± 18.2
DBP (mmHg) 81.5 ± 10.3
Table 1. Baseline characteristics (n = 427). Data presented as mean ± SD or as median (IQR) or as numbers of 
participants (%); BMI, body mass index; BSA, body surface areas; S/DBP, systolic/diastolic office blood pressure.
Male (n = 195) Female (n = 210)
Sokolow-Lyon (mV) 21.1 ± 6.5 19.0 ± 5.3
Sokolow-Lyon product (mV/s) 1860.8 ± 546.2 1626.5 ± 466.8
Cornell (mV) 12.9 ± 4.8 11.7 ± 4.8
Cornell Product (mV/s) 1209.9 ± 500 1015.5 ± 456.6
12 lead sum QRS voltage (mV) 129.3 ± 23.1 116 ± 22.3
12 lead sum QRS product (mV/s) 11932.6 ± 2844.8 10216 ± 2482.9
LVM (g) 143.9 ± 17.7 119.6 ± 17.1
Table 2. ECG indices of left ventricular hypertrophy. Data presented as mean ± SD; LVM, left ventricular mass. 
n = maximum number of phenotyped individuals available for heritability analysis.
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40 ± 11%). These estimates increased when the phenotype was expressed as a product with the QRS duration, 
the Sokolow-Lyon duration (h2QTDT, 57 ± 9%; h2IBS>0.05, 60 ± 10%); on paired statistics this was not statistically 
different (P-value = 0.7) from the heritability estimate of ECG LVM (h2QTDT, 62 ± 9%; h2IBS>0.05, 60 ± 10%).
CMR LV phenotypes all showed nominally significant evidence of heritability (P-value < 0.05), with LV 
end diastolic volume index showing the strongest evidence (h2QTDT, 42 ± 10%; h2IBS>0.05, 47 ± 12%). The CMR 
LVM showed weaker heritability compared to the ECG LVM (h2QTDT, 17 ± 9%; h2IBS>0.05, 27 ± 12%), although 
the difference was insignificant (heterogeneity P-value = 0.5). Figure 1 shows the intra-pair correlations for 1st 
and 2nd degree relative pairs that underpin the ECG and CMR LVM heritability estimates. Figure 2 shows corre-
lation between ECG and CMR LVM in males (a) (r = 0.47) and females (b) (r = 0.46), respectively. On Fisher’s 
z-transformation there was no significant difference in these correlations (P-value = 0.9). For the combined group 
the rho is 0.65. Supplementary Figure 1 also shows correlation between ECG LVM adjusted for height and CMR 
LVM in males (a) (r = 0.41) and females (b) (r = 0.37), respectively (Fisher z-transformation P-value = 0.65).
Supplementary Tables 4 and 6 show heritability estimates for CMR right ventricular (RV) and chest dimen-
sional phenotypes. Several of the RV traits show evidence of heritability, the strongest being RV mass and RV 
mass index (h2QTDT, 44 ± 9%; h2IBS>0.05, 45 ± 12%). Amongst the chest size phenotypes, chest lateral diameter 
showed the strongest evidence of heritability (h2QTDT, 60 ± 11%; h2IBS>0.05, 60 ± 11%). We found that chest lateral 
diameter showed a strong correlation with ECG LVM in our data (rho = 0.67, P-value = 4 × 10−50) raising the 
hypothesis that the ECG LVM heritability estimate is inflated due to confounding with chest size. We therefore 
re-examined the ECG LVM phenotype allowing for significant (P-value < 0.01) covariation in CMR chest lateral 
diameter, height and treatment-adjusted SBP, the resulting ECG LVM heritability estimate was duly attenuated 
(h2QTDT, 42 ± 16%; h2IBS>0.05, 43 ± 11%, Table 4).
Supplementary Tables 2 and 6 report heritability estimates for several anthropometric phenotypes. Of 
note is the high heritability estimate for height (h2QTDT, 75 ± 8%; h2IBS>0.05, 84 ± 8%), a quantitative inherited 
trait proven highly tractable to GWAS9. Figure 3 illustrates the overall consistency of the variance-components 
(QTDT) and IBS threshold (GCTA-GREML) heritability estimates for the ECG and CMR LVM, and the anthro-
pometric traits. As expected with this sample number, the traits’ associations did not reach GWAS significance 
(P-value < 5 × 10−8).
Male (n = 195) Female (n = 210)
LVM (g) 149.2 ± 31.5 106.1 ± 23.2
LVM index (g/m2) 73.7 ± 13.5 59.3 ± 10.9
LV end-diastolic volume (mL) 149.4 ± 29.3 121.1 ± 25.1
LV end-diastolic volume index (mL/m2) 74.0 ± 13.9 67.7 ± 11.8
LV end-systolic volume (mL) 44.2 ± 12.3 33.9 ± 11.4
LV end-systolic volume index (mL/m2) 21.9 ± 6.0 19.0 ± 6.0
LVH (%) 22.6 22.1.1
Table 3. CMR measures of left ventricular hypertrophy. Data presented as mean ± SD. LVM, left ventricular 
mass; LVH, left ventricular hypertrophy. n = maximum number of individuals available for heritability analysis.
phenotype
number of 
phenotyped 
individuals
QTDT GCTA-GREML
h2QTDT (%) SE (%) P-value no. genotyped h2IBS>0.05 (%) SE (%) P-value
CMR
LVM 397 17 9 0.0469 362 27 12 0.0230
LVM index 397 17 8 0.0402 362 27 12 0.0196
LV end-diastolic volume 405 41 10 3.5E-05 369 47 12 7.2E-05
LV end-diastolic volume index 405 42 10 1.7E-05 369 47 12 5.9E-05
LV end-systolic volume* 397 32 10 0.0012 362 33 12 0.0049
LV end-systolic volume index* 397 35 10 0.0004 362 36 12 0.0019
ECG
Cornell voltage 404 25 9 7.4E-03 364 21 11 0.0541
Cornell duration 404 29 9 8.8E-04 364 26 11 0.0129
LVM† 404 62 9 3.5E-11 364 60 10 8.5E-09
LVM‡ 362 42 16 0.0087 330 43 11 2.2E-06
Sokolow-Lyon voltage 404 35 9 0.0001 364 40 11  0.0003
Sokolw-Lyon duration 403 57 9 9.7E-10 363 60 10  8.2E-0.9
Table 4. Heritability estimates for CMR and ECG LV phenotypes. LV, left ventricular. †LVM adjusted for 
significant (P-value < 0.01) covariation in height, treatment-adjusted SBP and DBP and sex, ‡LVM adjusted 
for significant (P-value < 0.01) covariation in CMR chest lateral diameter, height and treatment-adjusted SBP. 
*GCTA-GREML models were fitted without “–no-constrain” flag.
4Scientific RepoRtS |         (2019) 9:13556  | https://doi.org/10.1038/s41598-019-49961-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Discussion
We have revisited a family study in which we previously found that electrocardiographic parameters for LVH 
showed greater heritability than echocardiographic LVH measures3. We were uncertain as to whether those find-
ings simply reflected the imprecision of echocardiography in the quantification of anatomic LVM or were an indi-
cation that the biological foundations of electrocardiographic measures of hypertrophy were inherited differently 
from those of anatomic hypertrophy. In addition, there was also a possibility that the higher heritability of ECG 
traits, particularly the Sokolow-Lyon voltage, which uses chest lead voltage, indirectly reflected the heritability of 
chest dimensions.
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Figure 1. Scatter plots of left ventricular mass measures for pairs of relatives. The upper 3 plots show phenotype 
residuals following adjustment for covariation for cardiac MR left ventricular mass for sibling, parent-child or 
uncle/aunt-nephew/niece pairs; the lower plots show the corresponding residuals for the ECG left ventricular 
mass measurements. The number of phenotyped relative-pairs and the Pearson correlation coefficient (r) are 
shown above each plot.
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Figure 2. Correlations of cardiac MR and ECG measures of left ventricular (LV) mass in males (a) and females 
(b). Masses are unadjusted for potential sources of covariation.
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We therefore undertook to accurately assess the heritability of left ventricular phenotypes using CMR4,5. We 
also took advantage of the ability of the CMR to quantify right ventricular parameters to assess their heritability4. 
Furthermore, we used CMR to measure chest dimensions more precisely and assess their heritability relative to 
that of ECG indices of LVH.
We found very similar heritability estimates for three ECG phenotypes; Cornell voltage, Cornell duration, 
and Sokolow-Lyon voltage, to those reported in our previous study3. The ECG LVM heritability was though 
substantially larger (h2 ~ 0.6) than that reported (h2 ~ 0.18) in our previous study. Importantly, adjustment for 
co-variation in chest lateral dimension and height attenuated the ECG LVM heritability estimate (h2 ~ 0.42), 
suggesting that genetic influences on the highly heritable anthropometric indices that confound ECG LVM esti-
mates, as well as cardiac electrophysiological and anatomical factors, contribute to the high heritability. As ECG 
voltages are influenced by potential confounding factors that could inflate heritability, we adjusted ECG LVM for 
factors which showed association with ECG voltages. Blood pressure affects LVM, therefore treatment-adjusted 
SBP was included in the adjusted model. Surface ECG voltages incorporate not only the electrical signal from the 
myocardial mass, but also factors related to the length and constitution of the tissue path through which the signal 
travels. To account for this, the ECG voltages were adjusted for chest lateral diameter and height. The uncorrected 
values can be interpreted as the heritability of ECG LVM due not only to genes influencing myocardial mass itself, 
but also genes affecting blood pressure, body stature, and habitus. The corrected values provide an estimate of the 
heritability due to genes acting chiefly or solely on myocardial mass.
The CMR LVM heritability estimates (h2QTDT = 17%; h2IBS>0.05 = 27%) were comparable with those previously 
derived by echocardiography (h2 ~ 0.23). In contrast, RV mass showed more marked heritability (h2 ~ 0.44).
A key finding of the current study is that despite precise measurement of anatomic LVH using CMR, herita-
bility estimates were broadly unchanged from those we previously reported in the same cohort using echocardi-
ography3. In order to put our heritability estimates into context, we also estimated heritability for anthropometric 
traits and found, as expected, high estimates for phenotypes such as height, BSA, chest lateral diameter, weight, 
BMI, and chest volumes in descending order ranging from 84% to 40%. The contribution of these inflates the 
measured heritability of ECG measures of LVH, because of the effects of body habitus on the position of the heart 
and hence the electrocardiographic axes.
Several studies in different populations including the current cohort3 have reported heritability estimates for 
echocardiographic LVM ranging between 15 to 72%, with twin and sibling studies reporting higher estimates10–13. 
None of the studies examined heritability estimates for RV mass presumably because of the inherent difficulties 
in quantifying the right ventricle with echocardiography. We are aware of only one study that has reported herit-
ability estimates for CMR LVM and papillary muscle mass in twin pairs, which found heritability estimates of up 
to 84% for LVM, 76% for end-diastolic volumes, and 27% for end-systolic volumes14. Therefore our study is the 
first to report on heritability estimates for CMR LVM and volumes in a cohort of nuclear and extended families. 
We have also taken advantage of GWAS SNP information to confirm the heritability estimates using a statistical 
method that is unbiased by gene-gene interactions and shared environmental factors15. We further exploited the 
precision of CMR to quantify RV phenotypes to report for the first time heritability estimates for RV mass and 
volumes. To our surprise we found that the RV mass was more heritable than the LVM. The RV has a different 
embryological origin from the LV and both before and after birth it is exposed to different haemodynamic loads 
and stresses. Our findings suggest that genetic influence plays a larger role in determining RV mass than on the 
LVM. However, we are uncertain as to the prognostic implications of a higher RV mass.
The recognition that ECG measures of myocardial mass are heritable has motivated researchers to apply 
GWAS methods to test the “common disease/common variant” hypothesis and scan for underlying quantitative 
trait loci (QTL). A recent large-scale meta-analysis of QRS traits identified several dozen such QTL, each one of 
which had a small influence on these heritable traits16. Collectively the variants explained a small proportion of 
the total phenotype variation; 2.7% for Sokolow-Lyon voltage and 5.0% for QRS duration, so a considerable por-
tion of the anticipated heritability remains to be mapped (i.e. the “missing heritability”)17. Our findings suggest 
that genetic analyses of ECG LVM related phenotypes could be complicated by unrelated effects on chest size 
Figure 3. Comparison of heritability estimates from variance-component (QTDT) and IBS threshold (GCTA-
GREML) analysis. MR LV mass, cardiac MRI LVM; ECG LV mass, electrocardiographic LVM; BMI, body 
mass index; BSA, body surface area. The line-of-identity (i.e. Y = X) is indicated by a dashed line. The QTDT 
heritability estimate for ECG LVM after adjustment for chest size is shown by a solid triangle.
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and other anthropometric measures, or pleiotropic effects on both cardiac biology and body anatomy, or effects 
on cardiac biology unrelated to hypertrophy per se, such as conduction influences on QRS duration. Therefore, 
optimally precise and interpretable analyses will require CMR as well as ECG data to identify specific LVH QTL 
effects.
Methods
family ascertainment. Between 1993 and 1997, we recruited 248 families with 1425 members from Oxford 
for quantitative genetic study of hypertension and other cardiovascular risk factors3. Families were ascertained 
through a hypertensive proband (through a hospital hypertension service or via their family physicians) defined 
as daytime ambulatory blood pressure of >140/90 mmHg before the age of 65 years, a level which corresponds 
to the upper 5% of the distribution in Caucasian populations. This cohort comprises a panel of large extended 
white British families with adequate power to detect small genetic influence on quantitative traits18. For the cur-
rent study, a power calculation was performed to establish the minimum sample size adequate to retain power 
for detection of small genetic influences on LVM and to compare heritability of LVM defined by CMR vs. ECG 
(see Statistical Analysis, below). The Central Oxford Research Ethics Committee approved the study, and all 
subjects gave written informed consent. The investigation conforms to the principles outlined in the Declaration 
of Helsinki.
phenotyping. Participants were phenotyped at different time-points. In the 1st stage (1993–1997) we 
obtained demographic and anthropometric data, 24 h ambulatory blood pressure monitoring (ABPM), and 
blood samples for genetic analysis. In the 2nd stage (1999–2000), 955 subjects from 229 families were recalled for 
phenotyping with electrocardiography, echocardiography, carotid B-mode ultrasound (CIMT), assessment of 
baroreceptor sensitivity, bioimpedance, and 24 h hour urine collection for steroid analysis; these data were used 
in our previous LVH heritability analysis3. In the 3rd stage (2006–2008), 427 individuals from 116 families were 
recalled for CMR phenotyping. We also obtained ECG and contemporaneous 24 h ABPM, height, and weight 
measurements.
electrocardiography. 12-lead ECG was acquired from a supine position using the atria 6100 system (car-
dioscience, UK) recorded at 25 mm/s and 1 mV/cm without filter. ECGs were blindly analysed by MRN. Leads 
amplitudes [millivolts (mV)] were measured from an average of three consecutive complexes. QRS amplitudes 
were measured from the peak of the R wave to the nadir of either the Q wave or the S wave, according to the 
method of Siegel and Roberts19. R-wave amplitudes were measured to the nearest 0.05 mV and QRS duration to 
the nearest 40 milliseconds (msec) from the beginning of the Q wave to the end of the S wave. The Sokolow-Lyon 
index (SL) was SV1 + RV520. Cornell index (mV) was RaVL + SV3 in men and RaVL + SV3 + 0.6 mV in women 
as described21. The product (mV.ms) of these 2 indices was obtained by multiplying each one by the QRS duration 
in milliseconds. ECG LVM was calculated as 0·026 (RaVL + SV3) + 1·25 × weight + 34·4 for men; and 0·020 (Ra
VL + SV3) + 1·12 × weight + 36·2 for women22.
cMR image acquisition. CMR was performed on a 1.5 Tesla scanner (Sonata; Siemens Medical Solutions, 
Erlangen, Germany) with a dedicated six-channel phased array surface coil as described by our group, among 
others23. Imaging was performed during end-expiration breath-hold. Scout images in axial, sagittal, and cor-
onal planes were used to localise cardiac position and to plot double oblique, orthogonal, short and long axis 
imaging planes of the left ventricle. Segmented steady-state free precession (SSFP) cine imaging was performed 
for assessment of LV and RV volumes, mass and ejection fraction. Typical imaging parameters were as follows: 
repetition time (TR) 3.5 msec, echo time (TE) 1.6 msec, flip angle 60°, temporal resolution 35–40 msec, in-plane 
spatial resolution 1.9 mm × 1.4 mm. Images were acquired with a slice thickness of 7.0 mm and an interslice gap 
of 3.0 mm. The result was a horizontal long axis (HLA) image, a vertical long axis (VLA) image, and a left ven-
tricular outflow tract view (LVOT). Using the HLA and VLA views obtained, we obtained a SA stack beginning 
from the atrioventricular groove and covering the entire left and right ventricle. CMR images were analysed using 
Argus software (version 2002B; Siemens Medical Solutions, Erlangen, Germany). Blinded manual tracing of the 
epicardial and endocardial borders of successive short-axis slices was performed (by MRN) in the standard way 
at end-diastole (phase with the image with the largest LV and RV cavity) and end-systole (phase with the image 
with the smallest LV and RV cavity). Epicardial and endocardial borders were traced on the end-diastolic frame, 
with only an endocardial border traced on the end-systolic frame. The basal slice was selected for the left ventricle 
when at least 50% of the blood volume was surrounded by myocardium in both end-diastole and end-systole. 
The apical slice was defined as the final slice showing intracavity blood pool at both end-diastole and end-systole. 
Papillary muscles were included in the mass and excluded from volume calculations. From these data, LVM, 
ejection fraction, and end-diastolic and end-systolic volumes were calculated. Myocardial mass was determined 
as tissue volume × 1.05 g/cm3 (specific density of myocardium)24. The LVM and volumes were indexed to body 
surface area. Black blood axial images were used to measure the antero-posterior diameter, defined by a vertical 
line from the anterior surface of the vertebral body to the mid-point of the sternum as bony landmarks. The line 
was extended anteriorly and posteriorly to the surface of the overlying skin, as well as the chest lateral diameter 
defined as the longest distance from the left to the right side of the chest, roughly mid-axillary from each side. 
The chest volume was derived from scout coronal images and was calculated using the formula for calculating 
the volume of a cylindrical body, i.e. πr2h, where r is half the lateral chest diameter and h is the height of the chest 
measured from the base (centre of the diaphragm) to the centre of the thoracic inlet.
Genome-wide genotyping. DNA was extracted from whole blood by standard methods and quantified 
by a proprietary PicoGreen assay. Genotyping was performed using the Illumina 660W-Quad chip including 
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557,124 SNPs. Routine QC was undertaken using PLINK (version 1.9)25, to exclude SNPs with low call rates 
(<95%(-–geno 0.05)), individuals with low genotype rates (<95%(-–mind 0.05)), and SNPs with low minor 
allele frequency (<1% (-–maf 0.01)). Individuals with outlying heterozygosity were removed, as were SNPs that 
failed checks of Hardy-Weinberg Equilibrium (P-value < 1 × 10−8). Population stratification checks via principal 
components analysis with 1,000 Genome Projects individuals confirmed all participants were of European origin. 
Following QC, 503,855 autosomal SNPs were available for GCTA-GREML heritability analysis and family-based 
GWAS analysis.
Statistical analysis. Covariate adjustment. Linear regression modelling for covariate adjustment and 
the subsequent heritability analysis assume that the error distributions have an approximate normal density, 
we therefore used the boxcox procedure in the Stata™ (version 10.1) statistical analysis package to find the 
maximum likelihood parameters of the boxcox transform, and then transform the phenotype values accord-
ingly (Supplementary Table 2). Important (P-value < 0.01) sources of covariation such as age, gender, height, 
weight, body surface area (BSA), body mass index (BMI), SBP or DBP were identified via multiple linear regres-
sion by applying a forward-backwards stepwise procedure in Stata™ (version 10.1). SBP and DBP values were 
pre-adjusted for anti-hypertensive therapy by increasing SBP by 15 mm Hg and DBP by 10 mmHg26. Following 
covariate analysis, residual phenotype values were calculated and used in the subsequent heritability analyses.
Heritability and GWAS analyses. A variance-components heritability analysis was undertaken with the 
QTDT software27. Two statistical models, a general model that jointly estimated polygenic and random 
individual-specific effects was compared in a likelihood ratio test (LRT) with a nested random individual-specific 
effects-only model; standard errors (SE) of the resulting narrow-sense (additive effects-only) heritability esti-
mates (h2QTDT) were calculated by approximating the LRT as a Wald test. Our primary aim was to measure the 
heritability of left and right ventricular mass and volume as measured by CMR to compare with heritable ECG 
phenotypes. We anticipated that these would lie in the range 25–50%. Exploratory power calculations, using sim-
ulation techniques to model polygenic inheritance in the family-structures suggested that 427 participants from 
116 families would be sufficient to provide usefully precise estimates with a predicted sampling standard error of 
heritability estimate equal to 7.5%.
Genome-wide association (GWAS) data has been used to assess the overall heritability of phenotypes by fitting 
linear mixed-effects association models28. These estimates are complementary to those obtained from twin or 
familial correlation data analysed using variance-components models with the advantage that they are subject to 
less bias by epistasis (gene-gene interactions) or shared environmental factors. Yang’s method28 is however, itself 
biased when applied to mixtures of closely as well as distantly related individuals, an important consideration for 
the analysis of the extended families studied herein15. We therefore applied a single nucleotide polymorphism 
(SNP) driven, identity-by-state (IBS) threshold analytic approach to calculate h2IBS>0.05 heritability estimates; 
these estimates have been shown to accurately approximate fine-scale identity-by-descent (IBD) heritability esti-
mates to provide unbiased GWAS-based estimates of narrow-sense heritability15. The h2IBS>0.05 calculations were 
performed using revised GCTA-GREML software (version 1.26.0)29. Linear mixed modelling approaches account 
for population substructure and relatedness in genome-wide association studies. Family-based genome-wide 
association analyses were undertaken for each trait using FAST-LMM (version v2.07.20140304) using the–ML 
command for maximum likelihood parameter learning30.
Data Availability
GWAS summary statistics, relevant phenotype data, and analysis protocols are available from the authors on 
request.
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